Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017 by llinda3395

VIEWS: 28 PAGES: 3

This report provides insight about immunomodulators sales forecasts until 2017. Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.

More Info
									Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace
Antimetabolites as the Highest Value Sector by 2017


Immunosuppressants holds a 64% Market Share of the Immunomodulators
Market with More Products in the Pipeline than Immunostimulants

This report provides insight about immunomodulators sales forecasts until 2017.
Immunomodulators markets in the key geographies of the US, Europe and other relevant
regions are also covered in the report, as are immunomodulators R&D pipelines. The report
provides in-depth analysis and market forecasts of the major drug classes, which include
immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and
antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The
report also explores the competitive landscape, with a competitive analysis of the top
companies in the market.

GBI Research analysis estimated the global immunomodulators market to be valued at
$145.9 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 13.1% between
2002 and 2010. The market is forecast to grow at a CAGR of 8.6% between 2010 and 2017,
to reach $259.3 billion in 2017. In-depth analysis in the report is based on propriety
databases, primary and secondary research and in–house analysis by the GBI Research
team of experts.

GBI Research analysis found the R&D pipeline for the immunomodulators market to be
strong. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson &
Johnson are expanding into this market. This indicates that R&D activity for
immunomodulators will remain active for at least next four to five years.

Request a Sample for or Inquire before buying the report

Immunomodulators Market

Published: February 2012
No.OF Pages: 290
Price: Single User License US$ 3500      Corporate User License US$ 10500




Scope

* Data and analysis of the immunomodulators market in the leading geographies of the US
and Europe. Different drug classes of immunomodulators discussed in the report are
immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors,
antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines).
* Annualized market data for the immunomodulators market from 2002 to 2010, with
forecasts to 2017.
* Market data on the geographical landscape and therapeutic landscape, including market
sizes, market shares, annual costs of therapy and sales volumes
* Key drivers and restraints that have had significant impact on the market.
* Competitive landscape of the global immunomodulators market including benchmarking of
the top companies. The key companies studied in this report are Hoffman La Roche, Amgen,
Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly.

Reasons to buy

* Build effective strategies to launch pipeline products, by identifying potential geographies.
* Exploit in-licensing and out-licensing opportunities by identifying products to fill their
portfolio gaps.
* Develop key strategic initiatives by studying the key strategies of the top competitors.
* Develop market-entry and market expansion strategies, by identifying the geographic
markets poised for strong growth.
* Reinforce R&D pipelines by identifying new target mechanisms which can produce first–in-
class molecules with improved efficacy and safety profiles.

Major points covered in Table of Contents of this report include:

1 Table of Contents

2 Immunomodulators Market to 2017 - Market Introduction

3 Immunomodulators Market to 2017 - Market Characterization

4 Immunomodulators Market to 2017 - Geographical Landscape

5 Immunomodulators Market to 2017 - Immunosuppressants

6 Immunosuppressants - Antibodies

7 Immunosuppressants - Interferon Beta

8 Immunosuppressants - Glucocorticoids

9 Immunosuppressants - Calcineurin Inhibitors

10 Immunosuppressants - Antimetabolites

11 Immunomodulators Market to 2017 - Immunostimulants

12 Immunostimulants - Vaccines, Active Immunity

13 Immunostimulants: Antibodies - Passive Immunity

14 Immunostimulants: Interferon Alpha - Passive Immunity
15 Immunomodulators Market to 2017 - Competitive Landscape

16 Immunomodulators Market to 2017 - Strategic Consolidations

17 Immunomodulators Market to 2017 - Appendix

Explore Comprehensive list of more than 200 Tables & Figures available in the report @
http://www.reportsnreports.com/reports/145417-immunomodulators-market-to-2017-
immunosuppressant-antibodies-to-replace-antimetabolites-as-the-highest-value-sector-by-
2017.html

Contact:

Priyank Tiwari
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-391-5441
sales@reportsandreports.com
Visit our Market Research Blog @ http://www.reportsnreportsblog.com/

Connect With Us:

								
To top